Pharmaceutical News

RSS

ZYPREXA RELPREVV approved by FDA

The U.S. Food and Drug Administration (FDA) approved ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension for the treatment of schizophrenia in adults, Eli Lilly and Company announced today.

14 Dec 2009

Revolutions Medical begins mass manufacturing process for safety syringe

Revolutions Medical Corporation ("RevMed" or the "Company"), producers of the RevVac safety syringe, RevColor, RevDisplay and Rev3D MRI Technology, today announced that it has initiated the mass manufacturing process for the RevVac safety syringe, which is already FDA approved.

14 Dec 2009

Study supports the use of SinoFresh Nasal Spray to prevent and decrease H1N1 virus

SinoFresh HealthCare Products, Inc. announced the recent successful initial pilot animal study of the SinoFresh Nasal Spray product for use in preventing and decreasing the severity of H1N1 ("swine flu") virus.

14 Dec 2009

New technological system to help improve availability of anti-malarial drugs in Tanzania

A new solution developed by IBM ( IBM), Novartis and Vodafone with the Roll Back Malaria Partnership, is helping to save lives using everyday technology to improve the availability of anti-malarial drugs in remote areas of Tanzania.

14 Dec 2009

New eCTD document service speeds up drug approval process

The eCTD format was chosen partly because it makes copying, pasting, viewing, printing and annotating documents much easier. Yet making sure the documents are formatted properly can be a complex job involving a great deal of management and juggling.

14 Dec 2009

Oncolytics Biotech develops REOLYSIN for patients affected by hard-to-treat cancers

A novel class of cancer therapies called live biologics is offering new hope for patients affected by hard-to-treat cancers, according to two different studies testing the therapies in patients with sarcomas and head and neck cancers.

14 Dec 2009

Hormone therapy: An important treatment option for post-menopausal women

In connection with the New York Times’ recent coverage of hormone therapy1, Pfizer Inc. today released important facts and context to respond to the newspaper’s account. Pfizer believes the coverage is based on a misleading and selective reading of both the science and history of hormone therapy (HT) medicines.

14 Dec 2009

Trial date set for patent litigation in the U.S. District Court for the District of Delaware

Cubist Pharmaceuticals, Inc. today announced that a trial date has been set for patent litigation in the U.S. District Court for the District of Delaware against Teva Parenteral Medicines, Inc. (TPM), Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. alleging infringement of Cubist’s US Patent Nos. 6,468,967 and 6,852,689, which expire on September 24, 2019, and US Patent No. RE39,071, which expires on June 15, 2016.

14 Dec 2009

Synexus organises conference to raise awareness of the role of clinical research in drug development

Synexus in Poland organised the first ‘Importance of Clinical Trials in Medical Practice’ conference last week, in conjunction with Wroclaw Medical University. The event, targeting senior medical professionals, aimed to raise awareness of the role of clinical research in drug development and the importance of the business to Poland.

From AES - Accelerated Enrollment Solutions 14 Dec 2009

International experts prepare check-list for identifying insulin and cancer risk

Epidemiological studies are difficult to do well, pharmacoepidemiological studies are particularly complicated and studies of insulin and cancer risk are even more difficult to do well. "Well" in the sense that any association found can be interpreted in an unambiguous manner.

14 Dec 2009

Approval of injectable formulation using NanoCrystal technology announced

Elan Drug Technologies, a business unit of Elan Corporation, plc announces the approval by the Japanese Ministry of Health, Labour and Welfare of EMEND® (aprepitant) for the treatment of cancer chemotherapy-induced nausea and vomiting.

14 Dec 2009

Diabetic patients exposed to insulin glargine have higher incidence of cancer, shows study

Type 2 diabetes and obesity are linked to an increased risk of certain cancers. Recently published studies suggested that insulin glargine (a synthetic insulin preparation marketed under the trade name Lantus), may be associated with a higher risk of certain cancers than other insulins or oral glucose lowering medications.

14 Dec 2009

New biosensors show how schizophrenia drugs alter brain chemistry

Scientists have resolved a question about how a popular class of drugs used to treat schizophrenia works using biosensors that reveal previously hidden components of chemical communication in the brain.

14 Dec 2009

NICE guidelines limit options for low cost osteoporosis drugs

Low cost osteoporosis drugs are strictly rationed for the under 75s, and UK physicians hampered by restrictive guidelines, according to findings which appear today in the journal Therapeutic Advances in Musculoskeletal Disease, published by SAGE.

14 Dec 2009

Herb milk thistle help treat liver inflammation in cancer patients who receive chemotherapy, finds study

A new study finds that the herb milk thistle may help treat liver inflammation in cancer patients who receive chemotherapy. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that the herb could allow patients to take potent doses of chemotherapy without damaging their liver.

14 Dec 2009

Patients with elevated CRP and normal LDL levels may benefit from statin therapy

New research shows a long-term benefit in screening people for CRP, a marker for inflammation, even if they have normal levels of bad cholesterol, because of increased long-term risk for heart attack, stroke and death.

14 Dec 2009

Senators at odds about drug importation amendment

The New York Times: "Debating an overhaul of the health care system, the Senate found itself tied in knots on Thursday over a bipartisan proposal to allow people to import lower-cost prescription drugs from Canada and certain other countries."

13 Dec 2009

ChemGenex Pharmaceuticals and Hospira enter into exclusive agreement

ChemGenex Pharmaceuticals Limited and Hospira, Inc. announced today that they have entered into an exclusive agreement to license, develop and commercialize ChemGenex’s product candidate omacetaxine mepesuccinate, a novel targeted cytotoxic pharmaceutical product, in Europe, the Middle East and parts of Africa (the Territory).

13 Dec 2009

Forbes examines ongoing discussions over HIV/AIDS drugs patent pools

Forbes examines the ongoing discussions between aid groups and drug manufacturers over the formation of an HIV/AIDS drugs patent pool to help drive down costs for developing countries.

13 Dec 2009

FDA approves Mylan Pharmaceuticals' ANDA for Levetiracetam Tablets

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets, 1000 mg.

12 Dec 2009

Pharmaceutical News

ZYPREXA RELPREVV approved by FDA

Revolutions Medical begins mass manufacturing process for safety syringe

Study supports the use of SinoFresh Nasal Spray to prevent and decrease H1N1 virus

New technological system to help improve availability of anti-malarial drugs in Tanzania

New eCTD document service speeds up drug approval process

Oncolytics Biotech develops REOLYSIN for patients affected by hard-to-treat cancers

Hormone therapy: An important treatment option for post-menopausal women

Trial date set for patent litigation in the U.S. District Court for the District of Delaware

Synexus organises conference to raise awareness of the role of clinical research in drug development

International experts prepare check-list for identifying insulin and cancer risk

Approval of injectable formulation using NanoCrystal technology announced

Diabetic patients exposed to insulin glargine have higher incidence of cancer, shows study

New biosensors show how schizophrenia drugs alter brain chemistry

NICE guidelines limit options for low cost osteoporosis drugs

Herb milk thistle help treat liver inflammation in cancer patients who receive chemotherapy, finds study

Patients with elevated CRP and normal LDL levels may benefit from statin therapy

Senators at odds about drug importation amendment

ChemGenex Pharmaceuticals and Hospira enter into exclusive agreement

Forbes examines ongoing discussions over HIV/AIDS drugs patent pools

FDA approves Mylan Pharmaceuticals' ANDA for Levetiracetam Tablets

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News